ReviewWorld journal of microbiology & biotechnology2025
Antivirulence drugs against Acinetobacter baumannii: where do they stand?
Review in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Therapeutic challenges and emerging strategies against carbapenem-resistantCurrent research in microbial sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii is a nosocomial Gram-negative pathogen of multi- and extensive-drug resistance phenotypes. In certain regions, multi-drug resistance rates can soar as high as 80-90%. Accordingly, reports by the World Health Organization and the Centers for Disease Control and Prevention underscore the urgent need for developing new antibiotics against A. baumannii. With the scarcity of novel antibiotics against this pathogen in the development pipeline, its rapid ability to develop and acquire resistance, and its versatile virulence weaponry, antivirulence therapeutics that can attenuate its virulence without adversely affecting growth may represent a promising treatment option with less selective pressure for resistance development. This review summarizes different antivirulence strategies against A. baumannii, which have been preclinically tested in various in vivo models. We also review different challenges and opportunities related to the realization of A. baumannii antivirulence drugs for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.